Vaping

A FRESH warning has been issued over a major travel item that many of us now use, that actually poses a huge threat when flying.

Over the past couple of years, power banks have caused several issues across a number of flights.

In response, airlines have introduced new measures that specify the type of power bank you can or cannot take onboard.

As the school summer holidays approach, travellers are now being reminded to carry these items in their hand luggage.

Power banks contain lithium batteries, which according to the Civil Aviation Authority (CAA), pose a huge risk to aircraft, with more and more devices being found in hold luggage over the past year.

The aviation body also said that the average person now takes four different lithium-powered devices on a flight.

Read more on travel inspo

TRAVEL TIP

The £2.99 SIM hack that can save Brits HUNDREDS abroad

CHEAP BREAKS

UK’s best 100 cheap stays – our pick of the top hotels, holiday parks and pubs

However, they are prone to overheating, especially if they are defective and this can cause a fire.

The CAA states: “Passenger awareness remains low – over a third (36 per cent) of travellers are unaware of the dangers of packing batteries in checked baggage, even though 92 per cent fly with a mobile phone, 55 per cent with a laptop and 49 per cent with a power bank – suggesting hundreds of batteries could be incorrectly packed on a typical flight.”

While some airlines have responded to the increased use of lithium batteries by carrying containment bags – such as Virgin Atlantic and Wizz Air – they still pose the biggest risk of fire to flights.

And it’s not just power banks that have lithium batteries though and they aren’t anything new – you’ll also find them in your laptop, mobile and smart watch.

When an incident regarding a lithium battery occurs in the cabin, cabin crew can handle it more easily.

However, if the issue is in the hold it is a trickier problem to solve.

According to the CAA, there are around two lithium battery incidents every week.

And these incidents can cause delays as well as the plane diverting.

The rules to be aware of include taking items such as your mobile phone, vapes and power banks on board in the cabin.

If you are taking power banks, you are allowed a maximum of two and you cannot charge them during the flight.

Laptops must be switched off if they are in hold bags.

As part of its new campaign ‘Pack right, Safe flight’, the CAA added that travellers should “choose reputable suppliers and brands when buying devices and spare batteries” and that “batteries that show signs of damage, overheating, or swelling should not be used and should never be carried on an aircraft”.

Giancarlo Buono, Director of Aviation Safety at the UK Civil Aviation Authority said: “Flying is by far the safest way to travel, and we want to keep it that way.

“Pack right for a safe flight, and that means don’t put your batteries in your checked bag. Take them into the cabin with you.

“This simple tip will make your flight safer for you, and the other passengers you’re flying with.”

Here are the rules on batteries for some of the major airlines:

British Airways

You can take up to 15 battery-operated Personal Electronic Devices (PEDs) that contain lithium batteries such as laptops, tablets, smartphones, cameras, music players, smart baggage tags (e.g. Apple AirTag) onboard.

If in hand luggage, they must be switched off or placed in flight safe mode.

If in checked luggage, they must be completely switched off – not in sleep or hibernation mode.

You can only carry up to two power banks per person and they must be in the cabin in either the seat pocket or in a bag under the seat in front of you and they cannot exceed 100Wh.

Ryanair

Electronic devices and spare lithium batteries must be carried in the cabin only.

Each passenger can carry up to 15 electronic devices for personal use in the cabin “including but not limited to: smartphones, tablets, laptops, cameras, handheld gaming consoles, headphones”.

Each passenger can only carry up to two power banks and these are included in the overall limit of 20 spare lithium batteries – which cannot exceed 100Wh.

Ryanair adds: “Spare lithium batteries and power banks must be carried on the passenger’s person or in the under-seat cabin bag stowed under the seat in front.

“Power banks and spare lithium batteries must not be placed in cabin baggage stored in the overhead lockers.“

Power banks cannot be recharged when onboard or during the flight.

EasyJet

EasyJet has a limit of 15 electronic devices per passenger, which must be 12V or less and 100Wh or less.

When it comes to power banks, Wh ratings cannot exceed 160Wh for lithium batteries, and only two can be carried per passenger.

EasyJet states: “Power banks are prohibited from use on easyJet aircraft and must not be used to charge other devices.

“Power banks must be carried in carry-on baggage only, and it is recommended that power banks are carried where they can be monitore, d i.e. on your person.”

Virgin Atlantic

For Virgin Atlantic, you can travel with up to five spare batteries and/or power banks, depending on their watt-hour (Wh) rating.

All batteries and power banks must be able to fit inside the airline’s onboard Fire Containment Bag, which measures 37×28×10cm.

The airline states: “Please keep them in an accessible place during your flight — not in the overhead locker.

“Power banks cannot be plugged into your seat’s power supply at any time.

“Power banks cannot be used to charge other devices while onboard.

“Batteries and power banks must be under 100Wh.”

Wizz Air

For Wizz Air, power banks cannot be used during any phase of the flight, and they are not allowed in checked luggage.

Each traveller is limited to a maximum of 20 spare batteries, including a maximum of one power bank, which cannot exceed 100Wh.

The airline states: “Power banks and e-cigarettes should be carried where they can be monitored, i.e. on the person.”

WASHINGTON — The head of the Food and Drug Administration, Dr. Marty Makary, is resigning after a rocky tenure that drew months of complaints from health industry executives, anti-abortion activists, vaping lobbyists and other allies of President Trump.

He steps down after just over a year leading the powerful health regulatory agency, according to a White House official who was not authorized to speak before an announcement expected Tuesday and requested anonymity.

Kyle Diamantas, the agency’s chief for foods, will take over as acting commissioner, the official said. Diamantas is an attorney with personal ties to Donald Trump Jr.

A surgeon and health researcher, Makary came to prominence among Republicans as an outspoken critic of COVID-19 health measures during the pandemic when he frequently appeared on Fox News.

But he struggled to manage the FDA’s bureaucracy and failed to win the confidence of its staff after mass layoffs, leadership changes and a series of controversies in which the agency’s scientific principles appeared to be overridden by political interests, including those of Health Secretary Robert F. Kennedy Jr.

The FDA commissioner, as the leader of an agency that regulates billions of dollars in consumer goods and medicines, is often required to juggle competing priorities that straddle science and politics.

Makary faced a unique challenge in balancing calls by Trump and other Republicans to cut red tape at the FDA, while also tending to Kennedy’s interest in scrutinizing the safety of vaccines, drugs and food additives.

Virtually all of the FDA’s senior career officials resigned, retired or were forced out in the first year of the second-term Trump administration, leading to a steady stream of leaks and negative stories in the media cataloging low morale, dysfunction and frustration among staff.

Makary’s handpicked deputy, Dr. Vinay Prasad, was pushed out of the agency twice in less than a year for running afoul of specialty drugmakers and groups for patients with rare diseases. Makary appeared poised to weather the controversy, despite an ongoing pressure campaign calling on Trump to fire him.

Recent months brought fresh criticisms from other interest groups that the White House considers key to Republican chances in November elections.

Anti-abortion groups have criticized Makary for allegedly slow-walking an internal review of the abortion pill mifepristone, which has been on the market for 25 years but remains a target for conservative activists.

Vaping executives told Trump that Makary was blocking approval of their products, including new flavored e-cigarettes seen as crucial to the industry’s survival.

Last week, the agency abruptly changed course on vaping: authorizing the first fruit-flavored products and issuing guidelines that loosened marketing for major manufacturers. But it wasn’t enough to keep Makary in the job.

A permanent replacement for FDA commissioner will need to be nominated by Trump and confirmed by a majority vote in the Senate.

Faster drug reviews are overshadowed

As a former regular on Fox News, Makary was aggressive about promoting his accomplishments on cable television and podcasts and in online opinion pieces.

More than a half-dozen initiatives from Makary aimed to speed up or streamline FDA drug reviews, including dropping certain study requirements, incorporating artificial intelligence into drug evaluations and offering expedited reviews to medicines that support “national interests.”

But pharmaceutical executives rely on the predictability and consistency of FDA decisions, even more than speedy reviews. Makary’s efforts on drug reviews were overshadowed by internal conflicts and upheavals that created headaches for drugmakers, investors and patients.

A number of specialty drugmakers studying therapies for rare or hard-to-treat diseases said they received rejection letters or requests to run additional studies for drugs that previously had been given the go-ahead by FDA staff. Those drugs were primarily overseen by Prasad, who stepped down for a second time from his role as FDA’s vaccine and biotech chief in April.

Vaccine moves denounced

Prasad repeatedly overruled vaccine staffers to restrict eligibility for new COVID shots. In February, Prasad initially refused to even consider Moderna’s mRNA shot for flu. The FDA was forced to reverse itself after Moderna pledged to formally challenge the decision and called for intervention by the White House.

Some of Makary and Prasad’s most controversial vaccine proposals never came to fruition, despite stoking confusion and anxiety within the FDA and beyond.

In an internal memo in November, Prasad claimed — without publishing evidence — that the FDA had linked COVID shots to the deaths of 10 children. Prasad used that to justify a planned wholesale overhaul of the agency’s approach to approving and updating vaccines.

A dozen former FDA commissioners issued a scathing denunciation of the plan, warning that it would “undermine the public interest” and decimate vaccine development. The FDA has not released its analysis of the deaths or its plan for the vaccine overhaul.

FDA’s drug center had a revolving door

In the FDA’s drug center, which is the agency’s largest division, Makary oversaw a revolving door of leadership changes. Six people served as director over the course of one year.

Makary’s initial pick for the job, Dr. George Tidmarsh, was forced to resign after allegations that he used his FDA position to pursue a personal vendetta against a former business partner.

His replacement, longtime FDA cancer specialist Dr. Rick Pazdur, announced he would retire after just three weeks on the job, after clashing with Makary on multiple issues involving drug reviews.

With Makary’s departure, the fate of many fledgling initiatives is uncertain.

Most of the programs Makary introduced have not gone through federal rulemaking required to enshrine them in U.S. regulations and could easily be overturned by his successors.

Democrats in Congress have questioned the legality of some of those efforts, including a program that offers drugmakers expedited reviews for innovative medicines.

Perrone and Kim write for the Associated Press.